000			05626nam a2200349 a 4500
003			MX-TeUDD
005			20211004163320.0
008			030709s2002 pauad gr 001 0 eng c
020			_a0781720060
020			_a9780781720069
040			_aMX-TeUDD _bspa _cMX-TeUDD
041			_aeng
050	0	4	_aRC280.P7 _bR6 2002
245	0	0	_aProstate cancer : _bprinciples and practice / _cedición, Philip W. Kantoff, Peter R. Carroll, Anthony V. D'Amico.
246	2		_aPrinciples and practice.
260			_aPhiladelphia, U.S.A. : _bLippincott Williams & Wilkins, _c2002
300			_axv, 748 p. : _bil., gráf. ; _c29 cm.
500			_aCovers various aspects of diagnosis and screening and forms of accepted treatments of the prostate, with emphasis on the retention of sexual and physiological function. This work includes coverage of advanced androgen-sensitive and androgen-refractory disease. It also discusses the impact of advances in genetic understanding of prostate cancer.
504			_aIncluye referencias bibliográficas.
505	2		_aI. Biology.-- 1 Gross and Applied Anatomy of the Prostate.-- 2 Cellular and Molecular Biology of Prostatic Development.-- 3 Nuclear Receptors in Normal Prostatic Growth and Disease.-- 4 Somatic Genetics of Prostate Cancer: Oncogenes and Tumor Suppressors.-- 5 Antisurvival Therapy for Metastatic Prostate Cancer.-- 6 Evolution of Hormone-Refractory Prostate Cancer.-- 7 Prostate Cancer Prevention.-- II. Epidemiology.-- 8 Nutritional and Environmental Epidemiology of Prostate Cancer.-- 9 Genetic Epidemiology of Prostate Cancer.-- 10 Familial Prostate Cancer.-- 11 Race and Risk.-- 12 Conservative Management of Localized Prostate Cancer.-- 13 Clinical Epidemiology: Incidence Rates, Databases, Age, and Co-Morbidity.-- III. Diagnosis and Staging.-- 14 Screening for Prostate Cancer: Prostate-Specific Antigen, Digital Rectal Examination, and Free, Density, and Age-specific Derivatives 15 Serum Tumor Markers in Prostate Cancer.-- 16 Systematic Biopsy of the Prostate: Applications for Detection, Staging, and Risk Assessment.-- 17 Pathology.-- 18 Combined-Modality Staging in Predicting Prostate-Specific Antigen Outcome after Definitive Local Therapy for Men with Clinically Localized Prostate Cancer.-- 19 Imaging and Staging of Prostate Cancer.-- 20 Molecular Staging of Prostate Cancer.-- IV. Early Prostate Cancer-Single Modality Treatment.-- 21 Surgical Therapy of Clinically Localized Prostate Cancer Rationale. Patient Selection, and Outcomes.-- 22 External Beam Radiation Therapy: Conventional and Conformal.-- 23 Brachytherapy as Monotherapy.-- 24 New Methods of Focal Ablation of the Prostate.-- 25 Quality Of Life in Prostate Cancer.-- 26A Management Considerations of Urinary Incontinence and Erectile Dysfunction after Local Therapy for Prostate Cancer.-- 26B Management of Radiation Injury to the Bowel.-- 27 Management Considerations for the Patient With Low-Risk Disease.-- V. Early Prostate Cancer-multimodality Treatment.-- 28 Combined External Beam Radiation Therapy or Brachytherapy and Hormones.-- 29 Combination External Beam Radiation Therapy and Brachytherapy for Clinically Localized Prostate Cancer.-- 30 Proton Bearn Therapy in Prostate Cancer.-- 31 Neoadjuvant Androgen Deprivation Before Radical Prostatectomy for Prostate Adenocarcinoma.-- 32 Management of High-Risk Prostate Cancer.-- 33 Adjuvant External Beam Radiation Therapy Postprostatectomy.-- 34 Adjuvant Hormonal Therapy for Prostate Cancer.-- VI. Advanced Hormone Sensitive Disease.-- 35 Defining Treatment Failure after Local Treatment and Restaging.-- 36 Local Therapy for Recurrent Prostate Cancer.-- 37 Salvage Radiation after Radical Prostatectory.-- 38 Systemic Management Of The Patient With Prostate Cancer And A Rising Prostate-specific Antigen After Definitive Treatment.-- 39 Prognostic Factors for Response and Survival With Hormone Therapy.-- 40 Androgen Ablation for Prostate Cancer Mechanisms and Modalities.-- 41 Combined Androgen Blockade for the Treatment of Metastatic Caricer of the Prostate.-- 42 Alternative Hormone Approaches Intermittent. Penipheral, Triple.-- 43 Second Line Hormone Therapy.-- VII. Hormone-Refractory Disease.-- 44 Pain and Symptom Management.-- 45 Management of Bone Metastases. External Beam Radiation Therapy. Radiopharmaceuticals, and Bisphosphonates.-- 46 Hematologic Complications of Prostate Cancer.-- 47 Neurologic Complications of Prostate Cancer.-- 48 Orthopedic Considerations: Implications and Management of Metastatic Prostate Cancer.-- 49 Psychosocial Considerations in Prostate Cancer.-- VIII. Hormone Refractory Disease-Current Standards and Future Directions.-- 50 Clinical Trial Design for Prostate Cancer.-- 51 Chemotherapy for Androgen-Independent Prostate Cancer.-- 52 Novel Tumor-Directed Therapeutic Strategies for Hormone-Refractory Prostate Cancer.-- 53 Tumor Environment as the Target: Novel Therapeutics, Including Antiangiogenesis and Antimetastatics.-- 54 Cancer Vaccines and Genetic Immunotherapy for Prostate Cancer.-- 55 Complementary and Alternative Medicine.
546			_aTexto en inglés.
650		4	_aTumores prostásticos _919897
650		4	_aPróstata - _xCáncer. _920908
650		4	_aProstate - _xCáncer.
650		0	_aProstate - _xCancer.
700	1		_aD'Amico, Anthony V., _eed. _919900
700	1		_aKantoff, Philip, _eed. _919901
700	1		_aCarroll, Peter R., _eed. _919902
905			_aAcervo
906			_aRosy _b20030709
942			_cBK01 _2lcc
999			_c260820 _d260820